Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label, Placebo-controlled Dose Escalation Study to Evaluate Safety and Pharmacokinetics of Natrunix Via Subcutaneous Injection in Healthy Subjects

NCT05099510 is registered in ClinicalTrials.gov with XBiotech, Inc. as lead sponsor.

NCT NCT05099510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05099510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label, Placebo-controlled Dose Escalation Study to Evaluate Safety and Pharmacokinetics of Natrunix Via Subcutaneous Injection in Healthy Subjects
Lead sponsor
XBiotech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 19, 2022
Completion date
August 8, 2022
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics